We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Philip Newsome

Philip Newsome PhD, FRCPE

Professor of Hepatology, University of Birmingham; Director, Centre for Liver and Gastrointestinal Research; Consultant Hepatologist, Liver Unit, Queen Elizabeth Hospital, Birmingham; Deputy Director, Birmingham NIHR Biomedical Research Centre (BRC); Director, Midlands & Wales Advanced Therapy Treatment Centre; Director of Research and Knowledge Transfer, College of Medical & Dental Sciences, University of Birmingham, Birmingham, United Kingdom

Phil Newsome is Professor of Hepatology, Director of the Centre for Liver and Gastrointestinal Research at the University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital in Birmingham, United Kingdom. Professor Newsome is also the Deputy Director for the Birmingham NIHR Biomedical Research Centre (BRC) and the Director of the Midlands & Wales Advanced Therapy Treatment Centre.

Professor Newsome runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD.

He has published 198 papers (99 since 2016). Cited 11280 times; h index of >50. Raised >£50M in grant income with £20M active funding.

He undertook pivotal studies on community prevalence (J.Hep 2012) and natural history (Gastroenterology 2020) and developed new strategies for determining NAFL severity (Gastro 2020/Lancet GH 2020 – FAST score). He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapies in NAFLD published in the Lancet and the NEJM. He is the Co-ordinating Investigator for several global NAFLD studies. He is an editor of a recently published textbook on Liver Transplantation, chaired the national guidelines for liver transplantation in NAFLD and sat on the NICE Guideline Development Group for NAFLD. He led the recent UK multi-stakeholder guideline group on the management of abnormal liver blood tests and led on NAFLD for the recent EASL Lancet Liver Commission. He recently completed his term as Secretary General (President) of EASL.

Professor Newsome’s research portfolio has led to high impact publications throughout, including both original articles (NEJM, PNAS, Gastroenterology, Hepatology, Journal of Hepatology, Gut, American Journal of Transplantation, Annals of Internal Medicine, Lancet, Nature and Nature Comms) and review articles (FASEB, Gastroenterology, Journal of Hepatology).